<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="gsd2" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">gsd2</book-part-id>
      <title-group>
        <title>Pompe Disease</title>
        <alt-title alt-title-type="alt-title">Synonyms: Acid Alpha-Glucosidase Deficiency, Acid Maltase Deficiency, GAA Deficiency, Glycogen Storage Disease Type II (GSD II), Glycogenosis Type II</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Nancy</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Cincinnati STAR Center for Lysosomal Diseases<break/>Division of Human Genetics<break/>Cincinnati Children's Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>nancy.leslie@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bailey</surname>
            <given-names>Laurie</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Cincinnati STAR Center for Lysosomal Diseases<break/>Division of Human Genetics<break/>Cincinnati Children's Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>laurie.bailey@cchmc.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>31</day>
          <month>8</month>
          <year>2007</year>
        </date>
        <date date-type="updated">
          <day>11</day>
          <month>5</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>5</day>
          <month>8</month>
          <year>2008</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="poly" document-type="chapter">Polymicrogyria Overview</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="potocki-lupski" document-type="chapter">Potocki-Lupski Syndrome</related-object>
      <abstract id="gsd2.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Pompe disease is classified by age of onset, organ involvement, severity, and rate of progression.</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">Infantile-onset Pompe disease</italic> (IOPD; individuals with onset before age 12 months with cardiomyopathy) may be apparent in utero but more typically onset is at the median age of four months with hypotonia, generalized muscle weakness, feeding difficulties, failure to thrive, respiratory distress, and hypertrophic cardiomyopathy. Without treatment by enzyme replacement therapy (ERT), IOPD commonly results in death by age two years from progressive left ventricular outflow obstruction and respiratory insufficiency.</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">Late-onset Pompe disease</italic> (LOPD; including: (a) individuals with onset before age 12 months without cardiomyopathy; and (b) all individuals with onset after age 12 months) is characterized by proximal muscle weakness and respiratory insufficiency; clinically significant cardiac involvement is uncommon.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of GSD II is established in a proband with either deficiency of acid alpha-glucosidase enzyme activity or biallelic pathogenic variants in <italic toggle="yes">GAA</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management guidelines from the American College of Medical Genetics: individualized care of cardiomyopathy as standard drugs may be contraindicated and risk for tachyarrhythmia and sudden death is high; physical therapy for muscle weakness to maintain range of motion and assist in ambulation; surgery for contractures as needed; nutrition/feeding support. Respiratory support may include inspiratory/expiratory training in affected adults, CPAP, BiPAP, and/or tracheostomy.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Begin enzyme replacement therapy (ERT) with alglucosidase alfa as soon as the diagnosis is established. Of note, ERT can be accompanied by infusion reactions (which are treatable) as well as anaphylaxis. Infants at high risk for development of antibodies to the therapeutic enzyme are likely to need immunomodulation early in the treatment course.</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">IOPD.</italic> In the pivotal trial, a majority of infants in whom ERT was initiated before age six months and before the need for ventilatory assistance showed improved survival, ventilator-independent survival, improved acquisition of motor skills, and reduced cardiac mass compared to untreated controls. More recent data suggest that initiation of ERT before age two weeks may improve motor outcomes in the first two years of life, even when compared to infants in whom treatment was initiated only ten days later.</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">LOPD.</italic> ERT may stabilize the functions most likely to be lost: respiration and motor ability.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Aggressive management of infections; keeping immunizations up to date; annual influenza vaccination of the affected individual and household members; respiratory syncytial virus (RSV) prophylaxis (palivizumab) in the first two years of life; use of anesthesia only when absolutely necessary.</p>
          <p><italic toggle="yes">Surveillance:</italic> Routine monitoring of respiratory status, cardiovascular status, musculoskeletal function (including bone densitometry), nutrition and feeding, renal function, and hearing.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Digoxin, ionotropes, diuretics, and afterload-reducing agents, as they may worsen left ventricular outflow obstruction in some stages of the disease; hypotension and volume depletion; exposure to infectious agents.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Evaluate at-risk sibs to permit early diagnosis and treatment with ERT.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Pompe disease is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. If the <italic toggle="yes">GAA</italic> pathogenic variants in an affected family member are known, carrier testing for at-risk family members, prenatal testing for pregnancies at increased risk, and preimplantation genetic diagnosis are possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="gsd2.Diagnosis">
        <title>Diagnosis</title>
        <p>Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Infantile-onset Pompe disease (IOPD).</bold> Individuals with onset before age 12 months with cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>
              <bold>Late-onset Pompe disease (LOPD)</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Individuals with onset before age 12 months without cardiomyopathy; and</p>
              </list-item>
              <list-item>
                <p>All individuals with onset after age 12 months</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <sec id="gsd2.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Infantile-onset and late-onset Pompe disease <bold>are suspected</bold> in individuals with the following clinical findings and supportive laboratory findings.</p>
          <sec id="gsd2.Clinical_Findings">
            <title>Clinical Findings</title>
            <p><bold>Infantile-onset Pompe disease</bold>
<bold>(IOPD)</bold> is suspected in infants with the following [<xref ref-type="bibr" rid="gsd2.REF.van_den_hout.2003.332">van den Hout et al 2003</xref>, <xref ref-type="bibr" rid="gsd2.REF.kishnani.2006a.671">Kishnani et al 2006a</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Poor feeding/failure to thrive (44%-97% of cases)</p>
              </list-item>
              <list-item>
                <p>Motor delay/muscle weakness (20%-63%)</p>
              </list-item>
              <list-item>
                <p>Respiratory infections/difficulty (27%-78%)</p>
              </list-item>
              <list-item>
                <p>Cardiac problems (shortened PR interval with a broad, wide QRS complex, cardiomegaly, left ventricular outflow obstruction, cardiomyopathy) (50%-92%)</p>
              </list-item>
            </list>
            <p><bold>Late-onset Pompe disease (LOPD)</bold> is suspected in infants, children, and adults with proximal muscular weakness and respiratory insufficiency without clinically apparent cardiac involvement.</p>
          </sec>
          <sec id="gsd2.Supportive_Laboratory_Findings">
            <title>Supportive Laboratory Findings</title>
            <p><bold>Positive newborn screening (NBS) results.</bold> Rapid and sensitive analysis of acid alpha-glucosidase (GAA) enzyme activity can be performed on dried blood spots when using standard conditions [<xref ref-type="bibr" rid="gsd2.REF.chamoles.2004.97">Chamoles et al 2004</xref>, <xref ref-type="bibr" rid="gsd2.REF.zhang.2006.302">Zhang et al 2006</xref>, <xref ref-type="bibr" rid="gsd2.REF.winchester.2008.275">Winchester et al 2008</xref>].</p>
            <p>Confirmation of deficiency of GAA enzyme activity detected on dried blood spots is recommended by molecular genetic testing [<xref ref-type="bibr" rid="gsd2.REF.winchester.2008.275">Winchester et al 2008</xref>]. Although measurement of GAA activity in another tissue (e.g., cultured skin fibroblasts) has been regarded as a &#x0201c;gold standard&#x0201d; for enzymatic diagnosis of Pompe disease, newer methodology using mass spectrometry suggests that blood-based assays may be comparable [<xref ref-type="bibr" rid="gsd2.REF.lin.2017.842">Lin et al 2017</xref>].</p>
            <p>Countries engaged in NBS include Taiwan, Austria [<xref ref-type="bibr" rid="gsd2.REF.mechtler.2012.335">Mechtler et al 2012</xref>], Japan [<xref ref-type="bibr" rid="gsd2.REF.oda.2011.560">Oda et al 2011</xref>] and the US (currently New York, Missouri, Kentucky, and Illinois; many more states are planning to implement NBS) [<xref ref-type="bibr" rid="gsd2.REF.hopkins.2015.172">Hopkins et al 2015</xref>].</p>
            <p><bold>Serum creatine kinase (CK) concentration</bold> is elevated (as high as 2000 IU/L; normal: 60-305 IU/L) in all individuals with IOPD and in some with LOPD (it may be normal in LOPD) [<xref ref-type="bibr" rid="gsd2.REF.lafor_t.2000.1122">Lafor&#x000ea;t et al 2000</xref>, <xref ref-type="bibr" rid="gsd2.REF.kishnani.2006b.267">Kishnani et al 2006b</xref>]. Because elevated serum CK concentration is observed in many conditions, it must be considered nonspecific.</p>
            <p><bold>Urinary oligosaccharides.</bold> Elevation of the specific urinary glucose, tetrasaccharide, is a highly sensitive finding in IOPD; however, it is also seen in other glycogen storage diseases [<xref ref-type="bibr" rid="gsd2.REF.an.2000.136">An et al 2000</xref>, <xref ref-type="bibr" rid="gsd2.REF.kallwass.2007.449">Kallwass et al 2007</xref>, <xref ref-type="bibr" rid="gsd2.REF.young.2012.50">Young et al 2012</xref>]. Sensitivity is diminished in LOPD [<xref ref-type="bibr" rid="gsd2.REF.young.2009.536">Young et al 2009</xref>]. Of note: Urinary oligosaccharides have been useful in evaluating infants with an abnormal result on NBS [<xref ref-type="bibr" rid="gsd2.REF.chien.2015.67">Chien et al 2015</xref>].</p>
          </sec>
        </sec>
        <sec id="gsd2.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of GSD II <bold>is established</bold> in a proband with either deficiency of acid alpha-glucosidase enzyme activity or biallelic pathogenic variants in <italic toggle="yes">GAA</italic> on molecular genetic testing (see <xref ref-type="table" rid="gsd2.T.summary_of_molecular_genetic_test">Table 1</xref>).</p>
          <p>Note: A single abnormal NBS result is not regarded as sufficient for diagnosis of Pompe disease.</p>
          <list list-type="bullet">
            <list-item>
              <p>The diagnosis of IOPD can be established rapidly after a positive NBS result when physical examination, echocardiography, and elevated CPK support the diagnosis.</p>
            </list-item>
            <list-item>
              <p>It is recommended that the diagnosis be confirmed either by molecular genetic testing [<xref ref-type="bibr" rid="gsd2.REF.winchester.2008.275">Winchester et al 2008</xref>] or by measurement of GAA activity in another tissue, such as isolated lymphocytes or mixed leukocytes. Note: Because of longer turn-around times, analysis of GAA enzyme activity in cultured skin fibroblasts is less ideal than molecular genetic testing or blood-based enzyme testing; however, it may be helpful when LOPD is suspected or when asymptomatic individuals are ascertained through screening tests.</p>
            </list-item>
          </list>
          <p><bold>Acid alpha-glucosidase (GAA) enzyme activity.</bold> Rapid and sensitive analysis of GAA enzyme activity can be performed on dried blood spots when using standard conditions [<xref ref-type="bibr" rid="gsd2.REF.chamoles.2004.97">Chamoles et al 2004</xref>, <xref ref-type="bibr" rid="gsd2.REF.zhang.2006.302">Zhang et al 2006</xref>, <xref ref-type="bibr" rid="gsd2.REF.winchester.2008.275">Winchester et al 2008</xref>]. Although other tissues such as muscle and peripheral leukocytes can be used, both have limitations.</p>
          <p>As a general rule, the lower the GAA enzyme activity, the earlier the age of onset of disease:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete deficiency of GAA enzyme activity (&#x0003c;1% of normal controls) is associated with IOPD.</p>
            </list-item>
            <list-item>
              <p>Partial deficiency of GAA enzyme activity (2%-40% of normal controls) is associated with LOPD [<xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>].</p>
            </list-item>
          </list>
          <p><bold>Molecular testing approaches</bold> can include <bold>single-gene testing</bold>, <bold>targeted analysis for pathogenic variants</bold>, and use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">GAA</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
              <p>Note: Caution must be exercised in correlating results from molecular genetic testing and enzyme analysis in the absence of clinical features of Pompe disease as the pseudodeficiency allele c.1726 G&#x0003e;A (p.Gly576Ser), which is relatively common in Asian populations, interferes with interpretation of enzyme testing in NBS programs (confirmed by screening programs in Missouri and New York) [<xref ref-type="bibr" rid="gsd2.REF.hopkins.2015.172">Hopkins et al 2015</xref>, <xref ref-type="bibr" rid="gsd2.REF.lin.2017.842">Lin et al 2017</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Targeted analysis for pathogenic variants</bold> can be performed before sequence analysis in individuals with the following ancestry and clinical findings:</p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>African Americans with IOPD.</bold> An estimated 50%-60% have the pathogenic variant <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Arg854Ter</xref> [<xref ref-type="bibr" rid="gsd2.REF.becker.1998.991">Becker et al 1998</xref>, <xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>].</p>
                </list-item>
                <list-item>
                  <p><bold>Chinese with IOPD.</bold> An estimated 40%-80% have the pathogenic variant <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Asp645Glu</xref> [<xref ref-type="bibr" rid="gsd2.REF.shieh.1998.306">Shieh &#x00026; Lin 1998</xref>, <xref ref-type="bibr" rid="gsd2.REF.ko.1999.380">Ko et al 1999</xref>, <xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>].</p>
                </list-item>
                <list-item>
                  <p><bold>Adults with LOPD.</bold> An estimated 50%-85% have the pathogenic variant <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">c.336-13T&#x0003e;G</xref> typically in the compound heterozygous state [<xref ref-type="bibr" rid="gsd2.REF.lafor_t.2000.1122">Lafor&#x000ea;t et al 2000</xref>, <xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>, <xref ref-type="bibr" rid="gsd2.REF.winkel.2005.875">Winkel et al 2005</xref>, <xref ref-type="bibr" rid="gsd2.REF.montalvo.2006.999">Montalvo et al 2006</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">GAA</italic> and other genes of interest (see <xref ref-type="sec" rid="gsd2.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included and sensitivity of multi-gene panels vary by laboratory and over time. (2) For this disorder a multi-gene panel that also includes deletion/duplication analysis is recommended (see <xref ref-type="table" rid="gsd2.T.summary_of_molecular_genetic_test">Table 1</xref>).</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="gsd2.T.summary_of_molecular_genetic_test" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Glycogen Storage Disease Type II</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">GAA</italic>
                  </td>
                  <td headers="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">83%-93%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_gsd2.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5%-13%&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd2.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="gsd2" object-id="gsd2.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="gsd2.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="gsd2.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="gsd2.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="gsd2.TF.1.4">
                <label>4. </label>
                <p>Detection rate of two pathogenic variants in sequencing of the genomic DNA in individuals with confirmed reduced or absent GAA enzyme activity [<xref ref-type="bibr" rid="gsd2.REF.hermans.2004.47">Hermans et al 2004</xref>, <xref ref-type="bibr" rid="gsd2.REF.montalvo.2006.999">Montalvo et al 2006</xref>].</p>
              </fn>
              <fn id="gsd2.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="gsd2.TF.1.6">
                <label>6. </label>
                <p>Deletion of exon 18 comprises approximately 5%-7% of alleles [<xref ref-type="bibr" rid="gsd2.REF.van_der_kraan.1994.1535">Van der Kraan et al 1994</xref>]. Although other exon and multiexon deletions have been reported, they are rare [<xref ref-type="bibr" rid="gsd2.REF.mccready.2007.325">McCready et al 2007</xref>, <xref ref-type="bibr" rid="gsd2.REF.pittis.2008.e27">Pittis et al 2008</xref>, <xref ref-type="bibr" rid="gsd2.REF.bali.2012.40">Bali et al 2012</xref>, <xref ref-type="bibr" rid="gsd2.REF.ami_oso.2013.169">Ami&#x000f1;oso et al 2013</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="gsd2.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="gsd2.Clinical_Description">
          <title>Clinical Description</title>
          <p>Traditionally, Pompe disease has been separated into two major phenotypes &#x02013; infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD) &#x02013;based on age of onset, organ involvement (i.e., presence of cardiomyopathy), severity, and rate of progression. As a general rule, the earlier the onset of manifestations, the faster the rate of progression; thus, the two general classifications &#x02013; IOPD and LOPD &#x02013; tend to be clinically useful in determining prognosis and treatment options.</p>
          <p>Although LOPD has been divided into childhood-, juvenile-, and adult-onset disease, many individuals with adult-onset disease recall symptoms beginning in childhood and, thus, late onset is often the preferred term for those presenting after age 12 months [<xref ref-type="bibr" rid="gsd2.REF.lafor_t.2000.1122">Lafor&#x000ea;t et al 2000</xref>]. Most likely, LOPD represents a clinical continuum in which age of onset cannot reliably distinguish subtype [<xref ref-type="bibr" rid="gsd2.REF.kishnani.2013.2431">Kishnani et al 2013</xref>].</p>
          <p><bold>IOPD</bold> may be apparent in utero but more often is recognized at a median age of four months as hypotonia, generalized muscle weakness, feeding difficulties, failure to thrive, and respiratory distress (see <xref ref-type="table" rid="gsd2.T.common_findings_at_presentation_o">Table 2</xref>).</p>
          <p>Feeding difficulties may result from facial hypotonia, macroglossia, tongue weakness, and/or poor oromotor skills [<xref ref-type="bibr" rid="gsd2.REF.van_gelder.2012.505">van Gelder et al 2012</xref>].</p>
          <p>Hearing loss is common, possibly reflecting cochlear or conductive pathology or both [<xref ref-type="bibr" rid="gsd2.REF.kamphoven.2004.14">Kamphoven et al 2004</xref>, <xref ref-type="bibr" rid="gsd2.REF.van_capelle.2010.597">van Capelle et al 2010</xref>].</p>
          <p>Without treatment by enzyme replacement therapy, the cardiomegaly and hypertrophic cardiomyopathy that may be identified in the first weeks of life by echocardiography progress to left ventricular outflow obstruction. Enlargement of the heart can also result in diminished lung volume, atelectasis, and sometimes bronchial compression. Progressive deposition of glycogen results in conduction defects as seen by shortening of the PR interval on ECG.</p>
          <p>In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency [<xref ref-type="bibr" rid="gsd2.REF.van_den_hout.2003.332">van den Hout et al 2003</xref>, <xref ref-type="bibr" rid="gsd2.REF.kishnani.2006a.671">Kishnani et al 2006a</xref>].</p>
          <table-wrap id="gsd2.T.common_findings_at_presentation_o" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Common Findings at Presentation of Infantile-Onset Pompe Disease</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Physical Signs</th>
                  <th id="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Individuals&#x000a0;<sup>1</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hypotonia/muscle weakness</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">52%-96%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiomegaly</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">92%-100%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hepatomegaly</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">29%-90%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Left ventricular hypertrophy</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">83%-100%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiomyopathy</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">88%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Respiratory distress</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">41%-78%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Murmur</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">46%-75%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Enlarged tongue (macroglossia)</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">29%-62%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Feeding difficulties</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">57%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Failure to thrive</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">53%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Absent deep tendon reflexes</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">33%-35%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Normal cognition</td>
                  <td headers="hd_h_gsd2.T.common_findings_at_presentation_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">95%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd2.TF.2.1">
                <label>1. </label>
                <p><xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser [2001]</xref>, <xref ref-type="bibr" rid="gsd2.REF.van_den_hout.2003.332">van den Hout et al [2003]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Death from ventilatory failure typically occurs in early childhood.</p>
          <p><bold>LOPD</bold> can manifest at various ages with muscle weakness and respiratory insufficiency. Disease progression is often predicted by the age of onset, as progression is more rapid if symptoms are evident in childhood.</p>
          <p>While initial manifestations in late childhood-onset to adolescent-onset Pompe disease do not typically include cardiac complications, some adults with late-onset disease have had arteriopathy, including dilation of the ascending thoracic aorta [<xref ref-type="bibr" rid="gsd2.REF.elgharbawy.2011.362">El-Gharbawy et al 2011</xref>]. Of note, echocardiography alone (without specific measurement of the diameter of the thoracic aorta) may not be sufficient to visualize this complication. In addition, ectasia of the basilar and internal carotid arteries may be associated with clinical signs, such as transient ischemic attacks and third nerve paralysis [<xref ref-type="bibr" rid="gsd2.REF.sacconi.2010.1730">Sacconi et al 2010</xref>].</p>
          <p>Progression of skeletal muscle involvement is slower than in the infantile forms and eventually involves the diaphragm and accessory respiratory muscles [<xref ref-type="bibr" rid="gsd2.REF.winkel.2005.875">Winkel et al 2005</xref>]. Affected individuals often become wheelchair users because of lower limb weakness. Respiratory failure causes the major morbidity and mortality [<xref ref-type="bibr" rid="gsd2.REF.hagemans.2005.671">Hagemans et al 2005</xref>, <xref ref-type="bibr" rid="gsd2.REF.g_ng_r.2011.34">G&#x000fc;ng&#x000f6;r et al 2011</xref>]. Male gender, severity of skeletal muscle weakness, and duration of disease are all risk factors for severe respiratory insufficiency [<xref ref-type="bibr" rid="gsd2.REF.van_der_beek.2011.129">van der Beek et al 2011</xref>].</p>
          <p>LOPD may present from the first decade to as late as the seventh decade of life with progressive proximal muscle weakness primarily affecting the lower limbs, as in a <related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter">limb-girdle muscular dystrophy</related-object> or polymyositis. Affected adults often describe symptoms beginning in childhood that resulted in difficulty participating in sports. Later, fatigue and difficulty with rising from a sitting position, climbing stairs, and walking prompt medical attention. In an untreated cohort of individuals with LOPD, the median age at diagnosis was 38 years, the median survival after diagnosis was 27 years, and the median age at death was 55 years (range 23-77 years) [<xref ref-type="bibr" rid="gsd2.REF.g_ng_r.2011.34">G&#x000fc;ng&#x000f6;r et al 2011</xref>].</p>
          <p>Evidence of advanced osteoporosis in adults with LOPD is accumulating; while this is likely in large part secondary to decreased ambulation, other pathologic processes cannot be overlooked [<xref ref-type="bibr" rid="gsd2.REF.oktenli.2000.412">Oktenli 2000</xref>, <xref ref-type="bibr" rid="gsd2.REF.case.2007.437">Case et al 2007</xref>].</p>
          <p><bold>Clinical manifestations of LOPD</bold> [<xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>]</p>
          <list list-type="bullet">
            <list-item>
              <p>Progressive proximal muscle weakness (95%) [<xref ref-type="bibr" rid="gsd2.REF.winkel.2005.875">Winkel et al 2005</xref>]</p>
            </list-item>
            <list-item>
              <p>Respiratory insufficiency</p>
            </list-item>
            <list-item>
              <p>Exercise intolerance</p>
            </list-item>
            <list-item>
              <p>Exertional dyspnea</p>
            </list-item>
            <list-item>
              <p>Orthopnea</p>
            </list-item>
            <list-item>
              <p>Sleep apnea</p>
            </list-item>
            <list-item>
              <p>Hyperlordosis and/or scoliosis</p>
            </list-item>
            <list-item>
              <p>Hepatomegaly (childhood and juvenile onset)</p>
            </list-item>
            <list-item>
              <p>Macroglossia (childhood onset)</p>
            </list-item>
            <list-item>
              <p>Difficulty chewing and swallowing</p>
            </list-item>
            <list-item>
              <p>GI symptoms, including irritable bowel- like symptoms</p>
            </list-item>
            <list-item>
              <p>Chronic pain</p>
            </list-item>
            <list-item>
              <p>Increased respiratory infections</p>
            </list-item>
            <list-item>
              <p>Decreased deep tendon reflexes</p>
            </list-item>
            <list-item>
              <p>Gower sign</p>
            </list-item>
            <list-item>
              <p>Joint contractures</p>
            </list-item>
          </list>
          <p><bold>Electrophysiologic studies.</bold> Myopathy can be documented by electromyography (EMG) in all forms of Pompe disease although some muscles may appear normal. In adults, needle EMG of the paraspinal muscles may be required to demonstrate abnormalities [<xref ref-type="bibr" rid="gsd2.REF.hobsonwebb.2011.2312">Hobson-Webb et al 2011</xref>].</p>
          <p>Nerve conduction velocity studies are normal for both motor and sensory nerves, particularly at the time of diagnosis in IOPD and in LOPD. However, an evolving motor axonal neuropathy has been demonstrated in a child with IOPD [<xref ref-type="bibr" rid="gsd2.REF.burrow.2010.455">Burrow et al 2010</xref>].</p>
          <p><bold>Muscle biopsy.</bold> In contrast to the other glycogen storage disorders, Pompe disease is also a lysosomal storage disease. In Pompe disease glycogen storage may be observed in the lysosomes of muscle cells as vacuoles of varying severity that stain positively with periodic acid-Schiff. However, 20%-30% of individuals with LOPD with documented partial GAA enzyme deficiency may not show these muscle-specific changes [<xref ref-type="bibr" rid="gsd2.REF.lafor_t.2000.1122">Lafor&#x000ea;t et al 2000</xref>, <xref ref-type="bibr" rid="gsd2.REF.winkel.2005.875">Winkel et al 2005</xref>]. Furthermore, while histochemical evidence of glycogen storage in muscle is supportive of a glycogen storage disorder it is not specific for Pompe disease.</p>
        </sec>
        <sec id="gsd2.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>GAA enzyme activity may correlate with age of onset and rate of progression as a "rough" general rule:</p>
          <list list-type="bullet">
            <list-item>
              <p>It is assumed that biallelic <italic toggle="yes">GAA</italic> pathogenic variants that produce essentially no enzyme activity result in infantile-onset Pompe disease (IOPD). Infants who have IOPD with no cross-reactive material (CRIM-negative) (see Management, <xref ref-type="sec" rid="gsd2.Prevention_of_Primary_Manifestation">Prevention of Primary Manifestations</xref>) are likely to have two null variants [<xref ref-type="bibr" rid="gsd2.REF.bali.2012.40">Bali et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Various combinations of other pathogenic variants resulting in some residual enzyme activity likely cause disease but the age of onset and progression are most likely directly proportional to the residual GAA enzyme activity.</p>
            </list-item>
          </list>
          <p>Some generalizations about genotype-phenotype correlations by type of pathogenic variant:</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">GAA</italic> pathogenic variants that introduce mRNA instability, such as nonsense variants, are more commonly seen in IOPD as they result in nearly complete absence of GAA enzyme activity.</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">GAA</italic> pathogenic missense and splicing variants may result in either complete or partial absence of GAA enzyme activity and therefore may be seen in both IOPD and LOPD [<xref ref-type="bibr" rid="gsd2.REF.zampieri.2011.422">Zampieri et al 2011</xref>].</p>
            </list-item>
          </list>
          <p>Some observations about genotype-phenotype correlations with specific pathogenic variants (see <xref ref-type="table" rid="gsd2.T.proportion_of_individuals_with_se">Table 3</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Glu176ArgfsTer45</xref> (c.525delT) is an especially common pathogenic variant among the Dutch [<xref ref-type="bibr" rid="gsd2.REF.van_der_kraan.1994.1535">Van der Kraan et al 1994</xref>]. It results in negligible GAA enzyme activity and must be considered one of the more severe alterations. Either in the homozygous state or in the compound heterozygous state with another severe pathogenic variant, p.Glu176ArgfsTer45 predicts IOPD, although the correlation is not absolute.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">Deletion of exon 18</xref> (p.Gly828_Asn882del; c.2482_2646del) is also a common pathogenic variant, particularly among the Dutch [<xref ref-type="bibr" rid="gsd2.REF.van_der_kraan.1994.1535">Van der Kraan et al 1994</xref>]. It results in negligible GAA enzyme activity and must be considered one of the more severe pathogenic variants. Deletion of exon 18, either in the homozygous state or in the compound heterozygous state with another severe pathogenic variant, predicts IOPD.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">c.336-13T&#x0003e;G</xref> is seen in 36% to 90% of late-onset GSD II and is not associated with IOPD [<xref ref-type="bibr" rid="gsd2.REF.hermans.2004.47">Hermans et al 2004</xref>, <xref ref-type="bibr" rid="gsd2.REF.montalvo.2006.999">Montalvo et al 2006</xref>]. The pathogenic variant leads to a leaky splice site resulting in greatly diminished, but not absent, GAA enzyme activity.</p>
            </list-item>
            <list-item>
              <p>The pathogenic variant <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Asp645Glu</xref>, seen in a high proportion (&#x02264;80%) of IOPD in Taiwan and China, is associated with a haplotype, suggesting a founder effect [<xref ref-type="bibr" rid="gsd2.REF.shieh.1998.306">Shieh &#x00026; Lin 1998</xref>].</p>
            </list-item>
            <list-item>
              <p>The pathogenic variant <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Arg854Ter</xref> is frequently associated with IOPD. Although present in several different ethnicities, this pathogenic variant has been observed in up to 60% of individuals of African descent who had a common haplotype, suggesting a founder effect [<xref ref-type="bibr" rid="gsd2.REF.becker.1998.991">Becker et al 1998</xref>].</p>
            </list-item>
          </list>
          <table-wrap id="gsd2.T.proportion_of_individuals_with_se" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Proportion of Individuals with Selected <italic toggle="yes">GAA</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">GAA</italic> Pathogenic Variant</th>
                  <th id="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Affected Individuals</th>
                  <th id="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Glu176ArgfsTer45</xref>
                  </td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">34% of Dutch population</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.van_der_kraan.1994.1535">Van der Kraan et al [1994]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">9% of US population</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.hirschhorn.1999.85">Hirschhorn &#x00026; Huie [1999]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Gly828_Asn882del</xref>
                  </td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">25% of Dutch &#x00026; Canadian infants</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.van_der_kraan.1994.1535">Van der Kraan et al [1994]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">5% of US population</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.hirschhorn.1999.85">Hirschhorn &#x00026; Huie [1999]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">c.336-13T&#x0003e;G</xref>
                  </td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">36%-90% of individuals w/late-onset GSD II</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="gsd2.REF.hermans.2004.47">Hermans et al [2004]</xref>, <xref ref-type="bibr" rid="gsd2.REF.montalvo.2006.999">Montalvo et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Asp645Glu</xref>
                  </td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02264;80% of Taiwanese &#x00026; Chinese infants</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.shieh.1998.306">Shieh &#x00026; Lin [1998]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="gsd2.T.gaa_variants_discussed_in_this_ge">p.Arg854Ter</xref>
                  </td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02264;60% of individuals of African descent w/a common phenotype</td>
                  <td headers="hd_h_gsd2.T.proportion_of_individuals_with_se_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.becker.1998.991">Becker et al [1998]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="gsd2.Nomenclature">
          <title>Nomenclature</title>
          <p>Historically, IOPD (now defined as onset before age 12 months with cardiomyopathy) was further divided into classic form (severe with onset age &#x0003c;12 months with clinically significant cardiomyopathy) and &#x0201c;non-classic&#x0201d; or infantile form (onset age &#x0003c;12 months but without cardiomyopathy) [<xref ref-type="bibr" rid="gsd2.REF.slonim.2000.283">Slonim et al 2000</xref>]. Most children with &#x0201c;non-classic IOPD&#x0201d; are now classified as LOPD (i.e., onset age &#x0003c;12 months without cardiomyopathy as well as all individuals with onset of myopathy age &#x0003e;12 months).</p>
        </sec>
        <sec id="gsd2.Prevalence">
          <title>Prevalence</title>
          <p>The incidence of Pompe disease varies, depending on ethnicity and geographic region, from 1:14,000 in African Americans to 1:100,000 in individuals of European descent (see <xref ref-type="table" rid="gsd2.T.incidence_of_pompe_disease_in_dif">Table 4</xref>).</p>
          <table-wrap id="gsd2.T.incidence_of_pompe_disease_in_dif" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Incidence of Pompe Disease in Different Populations</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Population</th>
                  <th id="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Incidence</th>
                  <th id="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">African American</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:14,000</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Netherlands</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:40,000 combined&#x000a0;<sup>1</sup><break/>1:138,000 infantile onset<break/>1:57,000 adult onset</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="gsd2.REF.ausems.1999.713">Ausems et al [1999]</xref>, <xref ref-type="bibr" rid="gsd2.REF.poorthuis.1999.151">Poorthuis et al [1999]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">US</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:40,000 combined</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.martiniuk.1998.69">Martiniuk et al [1998]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">South China/Taiwan</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:50,000</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.lin.1987.11">Lin et al [1987]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">European descent</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:100,000 infantile onset<break/>1:60,000 late onset</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.martiniuk.1998.69">Martiniuk et al [1998]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Australia</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:145,000</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.meikle.1999.249">Meikle et al [1999]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Portugal</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:600,000</td>
                  <td headers="hd_h_gsd2.T.incidence_of_pompe_disease_in_dif_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="gsd2.REF.pinto.2004.87">Pinto et al [2004]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gsd2.TF.4.1">
                <label>1. </label>
                <p>Combined = all Pompe disease phenotypes</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="gsd2.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">GAA</italic>.</p>
      </sec>
      <sec id="gsd2.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="gsd2.InfantileOnset_Pompe_Disease_IOPD">
          <title>Infantile-Onset Pompe Disease (IOPD)</title>
          <p>Disorders to be considered in the differential diagnosis:</p>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter"><bold>Spinal muscular atrophy 1</bold></related-object> (Werdnig-Hoffman disease, SMA I) is characterized by hypotonia, feeding difficulties, progressive proximal muscle weakness, and areflexia; no cardiac involvement. SMA I is caused by biallelic pathogenic variants in <italic toggle="yes">SMN1</italic>. Inheritance is autosomal recessive. Lack of cardiomegaly should help distinguish SMA1 from IOPD.</p>
            </list-item>
            <list-item>
              <p><bold>Danon disease</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300257">300257</ext-link>) is characterized by hypotonia, hypertrophic cardiomyopathy, and myopathy as a result of excessive glycogen storage; it is caused by a hemizygous pathogenic <italic toggle="yes">LAMP2</italic> variant in males and a heterozygous pathogenic <italic toggle="yes">LAMP2</italic> variant in females [<xref ref-type="bibr" rid="gsd2.REF.arad.2005.362">Arad et al 2005</xref>]. Inheritance is X-linked. Males are more severely affected than females, and the typical age of presentation with cardiomyopathy and weakness is in mid adolescence, although a few with infantile onset have been reported. In addition, intellectual disability may be present, which is unusual in Pompe disease.</p>
            </list-item>
            <list-item>
              <p><bold>Carnitine uptake disorder</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/212140">212140</ext-link>) is characterized by muscle weakness and cardiomyopathy without elevated serum CK concentration; it is caused by biallelic pathogenic variants in <italic toggle="yes">SLC22A5</italic>. Inheritance is autosomal recessive. Phenotypes vary widely, including asymptomatic women ascertained through newborn screening of their newborns. Acutely symptomatic infants may have encephalopathy or coma, which is unusual in Pompe disease.</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="gsd3" document-type="chapter"><bold>Glycogen storage disease type IIIa</bold></related-object> (debrancher deficiency) is characterized by hypotonia, cardiomegaly, muscle weakness, and elevated serum concentration of creatine kinase with more dramatic liver involvement than typically seen in Pompe disease. It is caused by biallelic pathogenic variants in <italic toggle="yes">AGL.</italic> Inheritance is autosomal recessive.</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="gsd4" document-type="chapter"><bold>Glycogen storage disease type IV</bold></related-object> (branching enzyme deficiency) is characterized by hypotonia, cardiomegaly, muscle weakness, and elevated serum concentration of creatine kinase with more dramatic liver involvement than typically seen in Pompe disease (similar to GSD IIIa). It is caused by biallelic pathogenic variants in <italic toggle="yes">GBE1</italic>. Inheritance is autosomal recessive.</p>
            </list-item>
            <list-item>
              <p><bold>Hypertrophic cardiomyopathy</bold> is characterized by biventricular hypertrophy without hypotonia or pronounced muscle weakness. See <related-object link-type="booklink" source-id="gene" document-id="hyper-card" document-type="chapter">Hypertrophic Cardiomyopathy Overview</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>Myocarditis</bold> is characerized by inflammation of the myocardium leading to cardiomegaly without hypotonia or muscle weakness.</p>
            </list-item>
            <list-item>
              <p><bold>Mitochondrial/respiratory chain disorders</bold> show wide variation in clinical presentation, and may include hypotonia, respiratory failure, cardiomyopathy, hepatomegaly, seizures, deafness, and elevated serum concentration of creatine kinase. They are often distinguishable from Pompe disease by the absence of hypotonia and presence of cognitive involvement. See <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>.</p>
            </list-item>
          </list>
        </sec>
        <sec id="gsd2.LateOnset_Pompe_Disease_LOPD">
          <title>Late-Onset Pompe Disease (LOPD)</title>
          <p>The early involvement of the respiratory muscles is often useful in distinguishing juvenile-onset Pompe disease from many neuromuscular disorders.</p>
          <p>Disorders to be considered in the differential diagnosis:</p>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter"><bold>Limb-girdle muscular dystrophy</bold></related-object><bold>.</bold> Progressive muscle weakness is seen in the legs, pelvis, and shoulders; with sparing of the truncal muscles. Inheritance is autosomal recessive, or less commonly autosomal dominant.</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="dbmd" document-type="chapter"><bold>Duchenne-Becker muscular dystrophy</bold></related-object><bold>.</bold> Progressive proximal muscle weakness, respiratory insufficiency, and difficulty ambulating are seen; the disorder primarily affects males. It is caused by a hemizygous <italic toggle="yes">DMD</italic> pathogenic variant in males. Inheritance is X-linked.</p>
            </list-item>
            <list-item>
              <p><bold>Polymyositis</bold> is characerized by progressive, symmetric, unexplained muscle weakness.</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="gsd5" document-type="chapter"><bold>Glycogen storage disease type V</bold></related-object> (McArdle disease; muscle glycogen phosphorylase deficiency). Elevated serum concentration of creatine kinase and muscle cramping with exertion. Biallelic pathogenic variants in <italic toggle="yes">PYGM</italic> are causative. Inheritance is autosomal recessive.</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="gsd6" document-type="chapter"><bold>Glycogen storage disease type VI</bold></related-object><bold>.</bold> Hypotonia, hepatomegaly, muscle weakness, and elevated serum concentration of creatine kinase are seen. Biallelic pathogenic variants in <italic toggle="yes">PYGL</italic> are causative. Inheritance is autosomal recessive.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="gsd2.Management">
        <title>Management</title>
        <sec id="gsd2.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Pompe disease, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110959/">guidelines</ext-link> have been published for the initial evaluation of individuals with:</p>
          <list list-type="bullet">
            <list-item>
              <p>Infantile-onset Pompe disease (IOPD) [American College of Medical Genetics expert panel; see <xref ref-type="bibr" rid="gsd2.REF.kishnani.2006b.267">Kishnani et al 2006b</xref>];</p>
            </list-item>
            <list-item>
              <p>Late-onset Pompe disease (LOPD) [<xref ref-type="bibr" rid="gsd2.REF.cupler.2012.319">Cupler et al 2012</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Chest radiography</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>IOPD</bold>. Nearly all affected infants have cardiomegaly on chest x-ray [<xref ref-type="bibr" rid="gsd2.REF.van_den_hout.2003.332">van den Hout et al 2003</xref>]. Further, evaluation of apparent lung volume reduction, areas of atelectasis, and any pulmonary fluid may be helpful in directing other therapies.</p>
            </list-item>
            <list-item>
              <p><bold>LOPD.</bold> Baseline radiographic evaluation of the lungs and heart silhouette is indicated but only rarely reveals cardiomegaly.</p>
            </list-item>
          </list>
          <p>
            <bold>Electrocardiography (ECG)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>IOPD.</bold> The majority of affected infants have left ventricular hypertrophy and many have biventricular hypertrophy [<xref ref-type="bibr" rid="gsd2.REF.van_den_hout.2003.332">van den Hout et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>LOPD.</bold> Based on findings of significant conduction abnormalities in four of 131 adults with LOPD, <xref ref-type="bibr" rid="gsd2.REF.sacconi.2014.648">Sacconi et al [2014]</xref> recommended Holter monitoring at initial evaluation.</p>
            </list-item>
          </list>
          <p>
            <bold>Echocardiography</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>IOPD.</bold> Typically echocardiography demonstrates hypertrophic cardiomyopathy with or without left ventricular outflow tract obstruction in the early phases of the disease process. In later stages, dilated cardiomyopathy may be seen.</p>
            </list-item>
            <list-item>
              <p><bold>LOPD.</bold> Echocardiographic assessment for dilatation of the ascending thoracic aorta has been recommended [<xref ref-type="bibr" rid="gsd2.REF.elgharbawy.2011.362">El-Gharbawy et al 2011</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Pulmonary</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>IOPD.</bold> Most infants have varying degrees of respiratory insufficiency. Respiratory status should be established with regard to cough, presence of wheezing or labored breathing, and/or feeding difficulties. Diaphragmatic weakness caused by excessive glycogen deposits results in mild to moderate reduction of vital capacity; however, objective assessment of pulmonary functions in infants is difficult at best. Most infants display respiratory difficulty with feeds or sleep disturbance [<xref ref-type="bibr" rid="gsd2.REF.kravitz.2005.a186">Kravitz et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>LOPD.</bold> Affected individuals should be evaluated for cough, wheezing, dyspnea, energy level, exercise tolerance, and fatigability. Formal pulmonary function tests show pulmonary insufficiency. An attempt to assess ventilatory capacity in the supine position can detect early ventilatory insufficiency. Pulse oximetry, respiratory rate, and venous bicarbonate and/or pCO<sub>2</sub> should be obtained to assess for alveolar hypoventilation [<xref ref-type="bibr" rid="gsd2.REF.van_der_beek.2011.129">van der Beek et al 2011</xref>, <xref ref-type="bibr" rid="gsd2.REF.cupler.2012.319">Cupler et al 2012</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Nutrition/feeding</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>IOPD.</bold> Patients should be evaluated for possible feeding difficulties (e.g., facial hypotonia, macroglossia, tongue weakness, and/or poor oromotor skills) [<xref ref-type="bibr" rid="gsd2.REF.jones.2010.277">Jones et al 2010</xref>, <xref ref-type="bibr" rid="gsd2.REF.van_gelder.2012.505">van Gelder et al 2012</xref>].</p>
              <p>Assessment of growth (i.e., height, weight, head circumference), energy intake, and feeding (including video swallow study) is appropriate.</p>
              <p>All infants should be evaluated for gastroesophageal reflux disease.</p>
            </list-item>
            <list-item>
              <p><bold>LOPD.</bold> Assessment of nutritional status as baseline is recommended. Assessment of swallowing difficulty by video swallow study may identify barriers to adequate nutrition and risk for aspiration. Gastrointestinal symptoms similar to those reported in patients with irritable bowel syndrome may be underreported in this population and may undermine quality of life.</p>
            </list-item>
          </list>
          <p><bold>Audiologic &#x02013;</bold>
<bold>IOPD</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>Baseline hearing evaluation including tympanometry is appropriate. See <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object> for a discussion of age-related methods of hearing evaluation.</p>
            </list-item>
            <list-item>
              <p>Sensorineural hearing loss is now documented in children with IOPD, and hearing aids may be of benefit [<xref ref-type="bibr" rid="gsd2.REF.van_capelle.2010.597">van Capelle et al 2010</xref>].</p>
            </list-item>
          </list>
          <p><bold>Disability inventory &#x02013;</bold>
<bold>IOPD and LOPD</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>All patients should undergo assessment of motor skills and overall functioning to guide subsequent therapies and monitor progression of the disease.</p>
            </list-item>
            <list-item>
              <p>Assessment of risk for falls is recommended.</p>
            </list-item>
          </list>
          <p><bold>Other.</bold> Consultation with a clinical geneticist and/or genetic counselor is recommended.</p>
        </sec>
        <sec id="gsd2.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110959/">Guidelines</ext-link> for the management of IOPD have been put forth by an expert panel from the American College of Medical Genetics [<xref ref-type="bibr" rid="gsd2.REF.kishnani.2006b.267">Kishnani et al 2006b</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Cardiomyopathy.</bold> Medical intervention needs to be individualized as use of standard drugs may be contraindicated in certain stages of the disease process (see <xref ref-type="sec" rid="gsd2.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>) [<xref ref-type="bibr" rid="gsd2.REF.kishnani.2006b.267">Kishnani et al 2006b</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Arteriopathy.</bold> Treatment does not differ from that in the general population.</p>
            </list-item>
            <list-item>
              <p><bold>Conduction disturbances.</bold> Patients with hypertrophic cardiomyopathy are at high risk for tachyarrhythmia and sudden death [<xref ref-type="bibr" rid="gsd2.REF.tabarki.2002.697">Tabarki et al 2002</xref>]; 24-hour Holter monitoring is useful in characterizing the type and severity of rhythm disturbance. Management includes avoidance of stress, infection, fever, dehydration, and anesthesia. Medical therapy, if indicated, often necessitates a careful balance of ventricular function and should be undertaken by a cardiologist familiar with Pompe disease.</p>
            </list-item>
            <list-item>
              <p><bold>Muscle weakness.</bold> Physical therapy is appropriate to maintain range of motion and assist in ambulation.</p>
              <p>Proximal motor weakness can result in contractures of the pelvic girdle in infants and children, necessitating aggressive management including surgery [<xref ref-type="bibr" rid="gsd2.REF.case.2012.69">Case et al 2012</xref>].</p>
              <p>Scoliosis is frequent, particularly in individuals with infantile- or childhood-onset disease [<xref ref-type="bibr" rid="gsd2.REF.roberts.2011.574">Roberts et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Difficulty with communication</bold> is common, and speech therapy as well as the use of augmented communication devices may be helpful.</p>
            </list-item>
            <list-item>
              <p><bold>Nutrition/feeding.</bold> Infants may need specialized diets and maximal nutrition, with some requiring gastric feedings.</p>
              <p>Persons with LOPD may also develop feeding concerns and are often managed on a soft diet, with a few requiring gastric or jejunal feedings.</p>
            </list-item>
            <list-item>
              <p><bold>Respiratory insufficiency.</bold> Respiratory support including CPAP and BiPAP may be required. Inspiratory/expiratory training has improved respiratory muscle strength in adults with LOPD [<xref ref-type="bibr" rid="gsd2.REF.jones.2011.417">Jones et al 2011</xref>].</p>
              <p>Macroglossia and severe respiratory insufficiency in the infantile form may necessitate tracheostomy.</p>
            </list-item>
          </list>
        </sec>
        <sec id="gsd2.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <sec id="gsd2.CRIM_Status">
            <title>CRIM Status</title>
            <p>Although enzyme replacement therapy (ERT) should be initiated as soon as the diagnosis of IOPD or symptomatic Pompe disease is established, it may be appropriate to determine cross-reactive immunologic material (CRIM) status prior to initiating ERT, as individuals who do not produce cross-reactive immunologic material (i.e., who are CRIM-negative) generally develop high titer anti-rhGAA antibodies during ERT and require modified therapy protocols using immunomodulation early in the treatment course, optimally before the first infusion [<xref ref-type="bibr" rid="gsd2.REF.winchester.2008.275">Winchester et al 2008</xref>, <xref ref-type="bibr" rid="gsd2.REF.kishnani.2010.26">Kishnani et al 2010</xref>, <xref ref-type="bibr" rid="gsd2.REF.messinger.2012.135">Messinger et al 2012</xref>]. Multiple immunomodulation protocols are in use, most of which use rituximab with additional drugs (including mycophenylate mofetil, methotrexate, and sirolimus) [<xref ref-type="bibr" rid="gsd2.REF.messinger.2012.135">Messinger et al 2012</xref>, <xref ref-type="bibr" rid="gsd2.REF.elder.2013.847">Elder et al 2013</xref>].</p>
            <p>Geographic areas in which CRIM-negative status is common include the US and the Middle East [<xref ref-type="bibr" rid="gsd2.REF.messinger.2012.135">Messinger et al 2012</xref>].</p>
            <p>Two ways to determine the CRIM status of an individual with Pompe disease are:</p>
            <list list-type="bullet">
              <list-item>
                <p>Acid alpha-glucosidase protein quantitation performed by an antibody-based method in cultured fibroblasts;</p>
              </list-item>
              <list-item>
                <p>Molecular genetic testing to determine if the pathogenic variants result in total absence of enzyme activity (i.e., are CRIM-negative) [<xref ref-type="bibr" rid="gsd2.REF.bali.2012.40">Bali et al 2012</xref>].</p>
              </list-item>
            </list>
          </sec>
          <sec id="gsd2.Enzyme_Replacement_Therapy_ERT">
            <title>Enzyme Replacement Therapy (ERT)</title>
            <p>Myozyme<sup>&#x000ae;</sup> (alglucosidase alfa) was approved by the FDA in 2006 for IOPD infantile-onset Pompe disease.</p>
            <p>Lumizyme<sup>&#x000ae;</sup> was approved by the FDA in 2010 for use in individuals older than age eight years with LOPD. Age restrictions on Lumizyme were removed in 2014.</p>
            <p>Myozyme<sup>&#x000ae;</sup> and Lumizyme<sup>&#x000ae;</sup> are administered by slow IV infusion at 20-40 mg/kg/dose every two weeks. Many individuals are now treated with the higher dose.</p>
          </sec>
          <sec id="gsd2.Complications_of_ERT">
            <title>Complications of ERT</title>
            <p><bold>Infusion-associated reactions.</bold> In clinical studies, infusion reactions were observed in half of those treated with Myozyme<sup>&#x000ae;</sup>.</p>
            <p>The majority of treated children developed IgG antibodies to Myozyme<sup>&#x000ae;</sup> within the first three months of treatment. Infusion reactions appear to be more common in individuals with IgG antibodies. Some affected individuals with high sustained IgG titers may have a poor clinical response to treatment (see <xref ref-type="sec" rid="gsd2.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>, <bold>Acid alpha-glucosidase protein quantitation</bold>).</p>
            <p>Development of IgE antibodies is less common but may be associated with anaphylaxis requiring life support measures.</p>
            <p>Most infusion-associated reactions can be modified by slowing the rate of infusion or administration of antipyretics, antihistamines, or glucocorticoids. For these reasons &#x02013; and because many individuals with IOPD have preexisting compromise of respiratory and cardiac function &#x02013; initiation of therapy in centers equipped to provide emergency care is recommended.</p>
            <p><bold>Other.</bold> Children with IOPD may have difficulty with anesthesia for procedures related to placement of devices for venous access.</p>
          </sec>
          <sec id="gsd2.Prognosis">
            <title>Prognosis</title>
            <p><bold>IOPD.</bold> The rationale for newborn screening (NBS) is that cardiac status and motor development in infants with IOPD treated early with enzyme replacement therapy (ERT) are better than in controls [<xref ref-type="bibr" rid="gsd2.REF.chien.2009.e1116">Chien et al 2009</xref>]; initiation of ERT before age two weeks is associated with significantly improved gross motor function at age 12 months [<xref ref-type="bibr" rid="gsd2.REF.yang.2016">Yang et al 2016</xref>]. Long-term follow-up data are not yet available on this cohort.</p>
            <p>In those in whom ERT was initiated before age six months and before the need for ventilatory assistance, a majority had improved survival, improved ventilator-independent survival, reduced cardiac mass, and significantly improved acquisition of motor skills compared to an untreated cohort.</p>
            <p>Longer-term survivors who underwent early ERT may show sustained improvement in cardiac and motor function [<xref ref-type="bibr" rid="gsd2.REF.prater.2012.800">Prater et al 2012</xref>]. ERT reduces cardiac mass to varying degrees and improves the ejection fraction, although there may be a transient decrease in the ejection fraction after the first several weeks of ERT [<xref ref-type="bibr" rid="gsd2.REF.levine.2008.1033">Levine et al 2008</xref>]. ERT results in an increase of the PR interval and a decrease in the left ventricular voltage [<xref ref-type="bibr" rid="gsd2.REF.ansong.2006.297">Ansong et al 2006</xref>].</p>
            <p>While the long-term prognosis is as yet unknown, available studies suggest better cognitive outcomes than had been predicted. Of note, assessment of cognitive abilities is difficult in children younger than age five years with IOPD; typical assessment tools frequently underestimate the cognitive abilities of these children [<xref ref-type="bibr" rid="gsd2.REF.kishnani.2009.329">Kishnani et al 2009</xref>, <xref ref-type="bibr" rid="gsd2.REF.nicolino.2009.210">Nicolino et al 2009</xref>, <xref ref-type="bibr" rid="gsd2.REF.ebbink.2012.1512">Ebbink et al 2012</xref>]. Estimates of cognitive abilities at age 24 months using the Bayley scales showed preservation of cognitive abilities in infants ascertained by NBS and treated early with ERT [<xref ref-type="bibr" rid="gsd2.REF.lai.2016.1617">Lai et al 2016</xref>].</p>
            <p>Pivotal trials of ERT on IOPD show convincing delay in the onset of dependence on ventilator support, but most patients who are ventilator dependent remain so . This finding is consistent with experimental evidence demonstrating relative resistance of skeletal muscle (especially type II fibers) to effective glycogen depletion with administered alpha glucosidase. Predictors of a poor response to ERT include increase in muscle glycogen during therapy, high IgG titers to alpha glucosidase, and CRIM negativity.</p>
            <p><bold>LOPD.</bold> The major morbidities are motor disability and respiratory insufficiency. In a randomized double-blind placebo-controlled study of 90 affected individuals age eight years and older who were ambulatory and free of invasive ventilatory support at baseline, those receiving the active agent had better preservation of motor function and forced vital capacity at the 78th week evaluation point [<xref ref-type="bibr" rid="gsd2.REF.van_der_ploeg.2010.1396">van der Ploeg et al 2010</xref>]. Similar findings were demonstrated in an open-label trial [<xref ref-type="bibr" rid="gsd2.REF.strothotte.2010.91">Strothotte et al 2010</xref>].</p>
            <p>Quality of life, assessed with the Rand Corporation 36-Item Short Form Survey Instrument (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.rand.org/health/surveys_tools/mos/36-item-short-form.html">SF-36</ext-link>), had declined in adults with LOPD before initiation of ERT and improved in the first two years of ERT [<xref ref-type="bibr" rid="gsd2.REF.g_ng_r.2016.253">G&#x000fc;ng&#x000f6;r et al 2016</xref>].</p>
            <p>Note: Although the timing of initiation of ERT in infants predicted to have LOPD who have been ascertained by newborn screening is not well established, the Taiwan group uses clinical severity to identify those for whom ERT is warranted before age three years [<xref ref-type="bibr" rid="gsd2.REF.chien.2015.67">Chien et al 2015</xref>].</p>
          </sec>
        </sec>
        <sec id="gsd2.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Infections need to be aggressively managed.</p>
          <p>Immunizations need to be kept current.</p>
          <p>Patients and household members should receive annual influenza vaccinations.</p>
          <p>Respiratory syncytial virus (RSV) prophylaxis (palivizumab) should be administered in the first two years of life.</p>
          <p>Anesthesia should be used only when absolutely necessary because reduced cardiovascular return and underlying respiratory insufficiency pose significant risks.</p>
        </sec>
        <sec id="gsd2.Surveillance">
          <title>Surveillance</title>
          <p>Close follow up is indicated. Management and surveillance <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110959/">guidelines</ext-link> have been proposed by the ACMG Work Group on Management of Pompe Disease [<xref ref-type="bibr" rid="gsd2.REF.kishnani.2006b.267">Kishnani et al 2006b</xref>]. Given the wide age range in individuals with LOPD, most of the recommendations can be applied to both IOPD and LOPD.</p>
          <list list-type="bullet">
            <list-item>
              <p>Twice-yearly clinical review of development, clinical status, growth, and use of adaptive equipment</p>
            </list-item>
            <list-item>
              <p>Assessment of respiratory status with each visit with regard to cough, difficulty breathing, wheezing, fatigability, and exercise tolerance:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Chest x-rays at regular intervals</p>
                </list-item>
                <list-item>
                  <p>Pulmonary function tests; yearly or more frequently as indicated</p>
                </list-item>
                <list-item>
                  <p>Periodic sleep evaluation, which may include regular capnography and pulse oximetry</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Monitoring of overall musculoskeletal and functional status to guide therapies aimed at preventing or minimizing physical impairment and its complications. This may include assessment for scoliosis and bone densitometry.</p>
            </list-item>
            <list-item>
              <p>Regular nutritional and feeding assessment</p>
            </list-item>
            <list-item>
              <p>At least annual renal function studies to monitor for secondary complications related to cardiac and/or pulmonary impairment as well as medication effects</p>
            </list-item>
            <list-item>
              <p>Annual cardiology evaluation in those with LOPD and as needed for those with IOPD:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Periodic echocardiography. Aortic dilatation has been detected by echocardiography in late-onset Pompe disease [<xref ref-type="bibr" rid="gsd2.REF.elgharbawy.2011.362">El-Gharbawy et al 2011</xref>].</p>
                </list-item>
                <list-item>
                  <p>24-hour ambulatory ECG (Holter monitoring) at regular intervals [<xref ref-type="bibr" rid="gsd2.REF.cook.2006.313">Cook et al 2006</xref>]. <xref ref-type="bibr" rid="gsd2.REF.sacconi.2014.648">Sacconi et al [2014]</xref> noted that enzyme replacement therapy did not prevent development of significant conduction abnormalities in four of 131 adults with LOPD.</p>
                </list-item>
                <list-item>
                  <p>Screening for cerebral arteriopathy with aneurysmal dilation and rupture leading to cerebral infarcts (strokes) and death, which have also been reported [<xref ref-type="bibr" rid="gsd2.REF.lafor_t.2008.2063">Lafor&#x000ea;t et al 2008</xref>, <xref ref-type="bibr" rid="gsd2.REF.sacconi.2010.1730">Sacconi et al 2010</xref>]. Screening strategies for these findings are being developed, but care teams should have a high index of suspicion for cerebral arteriopathy if an individual with late-onset Pompe disease develops unexplained stroke-like symptoms [<xref ref-type="bibr" rid="gsd2.REF.sacconi.2010.1730">Sacconi et al 2010</xref>].</p>
                  <p>Note: Individuals with LOPD may not be able to tolerate supine positioning in an MRI scanner due to diaphragmatic weakness.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Annual hearing evaluation</p>
            </list-item>
          </list>
        </sec>
        <sec id="gsd2.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Use of standard drugs for treatment of cardiac manifestations may be contraindicated in certain stages of the disease. The use of digoxin, ionotropes, diuretics, and afterload-reducing agents may worsen left ventricular outflow obstruction, although they may be indicated in later stages of the disease.</p>
          <p>Hypotension and volume depletion should be avoided.</p>
          <p>Exposure to infectious agents is to be avoided.</p>
        </sec>
        <sec id="gsd2.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic sibs of a proband so that morbidity and mortality can be reduced by early diagnosis and treatment with ERT.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the <italic toggle="yes">GAA</italic> pathogenic variants in the family are known.</p>
            </list-item>
            <list-item>
              <p>Testing of GAA enzyme activity if the <italic toggle="yes">GAA</italic> pathogenic variants in the family are not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="gsd2.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="gsd2.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Most individuals with infantile-onset Pompe disease (IOPD) have not reproduced.</p>
          <p>Many adults with late-onset Pompe disease (LOPD) have reproduced. At least one woman treated with ERT during pregnancy and lactation with no adverse effects on the fetus has been reported [<xref ref-type="bibr" rid="gsd2.REF.de_vries.2011.552">de Vries et al 2011</xref>]. As would be expected in a woman with a myopathy and respiratory insufficiency, the growing fetus may pose additional complications to the mother&#x02019;s health. Close respiratory and cardiac surveillance should be initiated in consultation with maternal fetal medicine specialists.</p>
        </sec>
        <sec id="gsd2.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Gene therapy to correct the underlying enzyme defect is under investigation [<xref ref-type="bibr" rid="gsd2.REF.raben.2002.145">Raben et al 2002</xref>, <xref ref-type="bibr" rid="gsd2.REF.deruisseau.2009.9419">DeRuisseau et al 2009</xref>, <xref ref-type="bibr" rid="gsd2.REF.mah.2010.502">Mah et al 2010</xref>]. A Phase I/II trial to investigate the ability of AAV-alpha glucosidase to improve ventilation reported outcomes of children with IOPD treated with ERT. In this trial of phrenic nerve injected AAV-alpha glucosidase and ventilatory training, the rate of ventilatory decline was attenuated in a subset of children, particularly those who were not already dependent on ventilatory assistance full time at the time of intervention [<xref ref-type="bibr" rid="gsd2.REF.smith.2017.216">Smith et al 2017</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="gsd2.Other">
          <title>Other</title>
          <p>Experience with bone marrow transplantation in both humans and cattle with acid alpha-glucosidase deficiency is limited; to date, such treatment is not considered successful [<xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>].</p>
        </sec>
      </sec>
      <sec id="gsd2.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="gsd2.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Pompe disease is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="gsd2.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In most instances, the parents of an affected child are heterozygotes (i.e., carriers of one <italic toggle="yes">GAA</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Survivors with treated infantile-onset Pompe disease (IOPD) are just now attaining reproductive age.</p>
            </list-item>
            <list-item>
              <p>The offspring of an individual with Pompe disease are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">GAA</italic>.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">GAA</italic> pathogenic variant.</p>
        </sec>
        <sec id="gsd2.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">GAA</italic> pathogenic variants in the family.</p>
          <p><bold>Biochemical genetic testing.</bold> Measurement of acid alpha-glucosidase enzyme activity in skin fibroblasts, muscle, or peripheral blood leukocytes is <bold>unreliable</bold> for carrier determination because of significant overlap in residual enzyme activity levels between obligate carriers and the general (non-carrier) population.</p>
        </sec>
        <sec id="gsd2.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="gsd2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Concordance/discordance of phenotype in family members.</bold> Sib pair concordance in IOPD is high in children with null pathogenic variants [<xref ref-type="bibr" rid="gsd2.REF.hirschhorn.2001">Hirschhorn &#x00026; Reuser 2001</xref>]. Age and severity of manifestations in LOPD may vary between affected family members.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="gsd2.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">GAA</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p><bold>Biochemical genetic testing.</bold> Prenatal testing is possible by measuring GAA enzyme activity in uncultured chorionic villi or amniocytes; however, molecular genetic testing is the preferred method if the familial pathogenic variants are known.</p>
        </sec>
      </sec>
      <sec id="gsd2.Resources">
        <title>Resources</title>
      </sec>
      <sec id="gsd2.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">GAA</italic> is approximately 20 kb in length and contains 20 exons. The cDNA is more than 3.6 kb in length with 2859 nucleotides of coding sequence.</p>
        <p><bold>Benign variants.</bold> Two benign variants (and the "normal" variant) are responsible for the three known alloenzymes (GAA1, GAA2, and GAA4).</p>
        <p>A pseudodeficiency allele c.1726 G&#x0003e;A (p.Gly576Ser), which interferes with enzyme activity toward artificial substrates, is relatively common in Asian as well as other populations studied as part of newborn screening programs [<xref ref-type="bibr" rid="gsd2.REF.labrousse.2010.379">Labrousse et al 2010</xref>, <xref ref-type="bibr" rid="gsd2.REF.hopkins.2015.172">Hopkins et al 2015</xref>, <xref ref-type="bibr" rid="gsd2.REF.lin.2017.842">Lin et al 2017</xref>]. Of note: Additional pseudodeficiency alleles are likely to be discovered through newborn screening.</p>
        <p><bold>Pathogenic variants.</bold> More than 150 pathogenic variants in <italic toggle="yes">GAA</italic> have been identified in individuals with Pompe disease. See <related-object source-id="gene" document-id="gsd2" object-id="gsd2.molgen.TA">Table A</related-object>.</p>
        <p>Pathogenic nonsense variants, large and small gene rearrangements, and splicing variants have been observed. Many pathogenic variants are potentially specific to families, geographic regions, or ethnicities.</p>
        <p>Combinations of pathogenic variants that result in complete absence of GAA enzyme activity are seen more commonly in infantile-onset Pompe disease (IOPD), whereas combinations of pathogenic variants that result in partial enzyme activity typically are seen more commonly in late-onset Pompe disease (LOPD).</p>
        <table-wrap id="gsd2.T.gaa_variants_discussed_in_this_ge" orientation="portrait" position="anchor">
          <label>Table 5. </label>
          <caption>
            <p><italic toggle="yes">GAA</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Pseudodeficiency</bold>
                </td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1726G&#x0003e;A</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly576Ser</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_4" rowspan="6" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/119393890">NM_000152.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/119393891">NP_000143.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.336-13T&#x0003e;G<break/>(IVS1-13T&#x0003e;G&#x000a0;<sup>1</sup>)</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.525delT</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Glu176ArgfsTer45</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1935C&#x0003e;A</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp645Glu</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2482_2646del<break/>(Exon 18 del)</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly828_Asn882del</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2560C&#x0003e;T</td>
                <td headers="hd_h_gsd2.T.gaa_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg854Ter</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="gsd2.TF.5.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> GAA is a lysosomal enzyme that catalyzes &#x003b1;-1,4- and &#x003b1;-1,6-glucosidic linkages at acid pH. There are seven glycosylation sites. The immature protein consists of 952 amino acids with a predicted non-glycosylated weight of 105 kd. The mature enzyme exists in either 76-kd or 70-kd form as a monomer.</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">GAA</italic> pathogenic variants result in mRNA instability and/or severely truncated acid alpha-glucosidase or an enzyme with markedly decreased activity.</p>
      </sec>
      <sec id="gsd2.References">
        <title>References</title>
        <sec id="gsd2.Published_GuidelinesConsensus_State">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="gsd2.Published_GuidelinesConsensus_State.reflist0">
            <ref id="gsd2.REF1">
              <mixed-citation publication-type="web">American College of Medical Genetics. Pompe disease diagnosis and management guideline. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110959/">online</ext-link>. 2006. Accessed 5-5-17.</mixed-citation>
            </ref>
            <ref id="gsd2.REF.cupler.2012.319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cupler</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leshner</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kissel</surname>
                    <given-names>JT</given-names>
                  </name>
                  <collab>AANEM Consensus Committee on Late-onset Pompe Disease</collab>
                </person-group>
                <article-title>Consensus treatment recommendations for late-onset Pompe disease.</article-title>
                <source>Muscle Nerve.</source>
                <year>2012</year>
                <volume>45</volume>
                <fpage>319</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">22173792</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gsd2.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="gsd2.Literature_Cited.reflist0">
            <ref id="gsd2.REF.ami_oso.2013.169">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ami&#x000f1;oso</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallespin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arrabal</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desviat</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solera</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Identification of the first deletion-insertion involving the complete structure of GAA gene and part of CCDC40 gene mediated by an Alu element.</article-title>
                <source>Gene.</source>
                <volume>519</volume>
                <fpage>169</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">23402890</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.an.2000.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>An</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hillman</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease.</article-title>
                <source>Anal Biochem</source>
                <volume>287</volume>
                <fpage>136</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">11078593</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.ansong.2006.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ansong</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nozik-Grayck</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ing</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kravitz</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Idriss</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanter</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Electrocardiographic response to enzyme replacement therapy for Pompe disease.</article-title>
                <source>Genet Med</source>
                <volume>8</volume>
                <fpage>297</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">16702879</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.arad.2005.362">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arad</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maron</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorham</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>WH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Saul</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Atayde</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spirito</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanter</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidman</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidman</surname>
                    <given-names>JG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Glycogen storage diseases presenting as hypertrophic cardiomyopathy.</article-title>
                <source>N Engl J Med</source>
                <volume>352</volume>
                <fpage>362</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">15673802</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.ausems.1999.713">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ausems</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbiest</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermans</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroos</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beemer</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wokke</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandkuijl</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>7</volume>
                <fpage>713</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10482961</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.bali.2012.40">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banugaria</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.</article-title>
                <source>Am J. Med Genet C Semin Med Genet</source>
                <volume>160C</volume>
                <fpage>40</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22252923</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.becker.1998.991">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raben</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagaraju</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermans</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brooks</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tifft</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirschhorn</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huie</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plotz</surname>
                    <given-names>PH</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The African origin of the common mutation in African American patients with glycogen-storage disease type II.</article-title>
                <source>Am J Hum Genet</source>
                <volume>62</volume>
                <fpage>991</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9529346</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.burrow.2010.455">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burrow</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinnett</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkin</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Acute progression of neuromuscular findings in infantile Pompe disease.</article-title>
                <source>Pediatr Neurol.</source>
                <volume>42</volume>
                <fpage>455</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20472203</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.case.2012.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckemeyer</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.</article-title>
                <source>Am J Med Genet C Semin Med Genet</source>
                <volume>160C</volume>
                <fpage>69</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">22252989</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.case.2007.437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frush</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krishnamurthy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeArmey</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boney</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Fractures in children with Pompe disease: a potential long-term complication.</article-title>
                <source>Pediatr Radiol</source>
                <volume>37</volume>
                <fpage>437</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">17342521</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.chamoles.2004.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chamoles</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niizawa</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaggioli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casentini</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.</article-title>
                <source>Clin Chim Acta</source>
                <volume>347</volume>
                <fpage>97</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">15313146</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.chien.2009.e1116">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thurberg</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>XK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Pompe disease in infants: improving the prognosis by newborn screening and early treatment.</article-title>
                <source>Pediatrics.</source>
                <volume>124</volume>
                <fpage>e1116</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">19948615</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.chien.2015.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolun</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaisnins</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening.</article-title>
                <source>JIMD Rep</source>
                <volume>19</volume>
                <fpage>67</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">25681082</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.cook.2006.313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carboni</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanter</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ansong</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kravitz</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>JS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.</article-title>
                <source>Genet Med</source>
                <volume>8</volume>
                <fpage>313</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16702882</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.cupler.2012.319_1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cupler</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leshner</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kissel</surname>
                    <given-names>JT</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Consensus treatment recommendations for late-onset Pompe disease.</article-title>
                <source>Muscle Nerve.</source>
                <year>2012</year>
                <volume>45</volume>
                <fpage>319</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">22173792</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.deruisseau.2009.9419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>DeRuisseau</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuller</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qiu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeRuisseau</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnelly</surname>
                    <given-names>WH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Mah</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reier</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Neural deficits contribute to respiratory insufficiency in Pompe disease.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <volume>106</volume>
                <fpage>9419</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">19474295</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.de_vries.2011.552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugma</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozkan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steegers</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>104</volume>
                <fpage>552</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21967859</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.ebbink.2012.1512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ebbink</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aarsen</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Gelder</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Hout</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weisglas-Kuperus</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaeken</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lequin</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arts</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.</article-title>
                <source>Neurology</source>
                <volume>78</volume>
                <fpage>1512</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22539577</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.elder.2013.847">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nayak</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herzog</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Modica</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lew</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.</article-title>
                <source>J Pediatr.</source>
                <year>2013</year>
                <volume>163</volume>
                <fpage>847</fpage>
                <lpage>54.e1</lpage>
                <pub-id pub-id-type="pmid">23601496</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.elgharbawy.2011.362">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>El-Gharbawy</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhat</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murillo</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thurberg</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered.</article-title>
                <source>Mol Genet Metab</source>
                <volume>103</volume>
                <fpage>362</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21605996</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.g_ng_r.2011.34">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000fc;ng&#x000f6;r</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagemans</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <volume>6</volume>
                <fpage>34</fpage>
                <pub-id pub-id-type="pmid">21631931</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.g_ng_r.2016.253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000fc;ng&#x000f6;r</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kruijshaar</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plug</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizopoulos</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanters</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wens</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>39</volume>
                <fpage>253</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">26531313</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.hagemans.2005.671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagemans</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkel</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loonen</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.</article-title>
                <source>Brain</source>
                <volume>128</volume>
                <fpage>671</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15659425</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.hermans.2004.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hermans</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Leenen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroos</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beesley</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakuraba</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijer</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelakakis</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirk</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosshard</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basel-Vanagaite</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besley</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>47</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">14695532</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.hirschhorn.1999.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hirschhorn</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huie</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Frequency of mutations for glycogen storage disease type II in different populations: the del525T and delexon 18 mutations are not generally "common" in white populations.</article-title>
                <source>J Med Genet</source>
                <volume>36</volume>
                <fpage>85</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9950376</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.hirschhorn.2001">
              <mixed-citation publication-type="book">Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> New York, NY: McGraw-Hill; 2001:3389-420.</mixed-citation>
            </ref>
            <ref id="gsd2.REF.hobsonwebb.2011.2312">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hobson-Webb</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dearmey</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings.</article-title>
                <source>Clin Neurophysiol</source>
                <volume>122</volume>
                <fpage>2312</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21570905</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.hopkins.2015.172">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hopkins</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klug</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogers</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raburn-Miller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiesling</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.</article-title>
                <source>J Pediatr.</source>
                <year>2015</year>
                <volume>166</volume>
                <fpage>172</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">25444528</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.jones.2011.417">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>104</volume>
                <fpage>417</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">21641843</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.jones.2010.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banugaria</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Grady</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Oropharyngeal dysphagia in infants and children with infantile pompe disease.</article-title>
                <source>Dysphagia</source>
                <year>2010</year>
                <volume>25</volume>
                <fpage>277</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">19763689</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kallwass.2007.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kallwass</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carr</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerrein</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Titlow</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pomponio</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skrinar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots.</article-title>
                <source>Mol Genet Metab</source>
                <volume>90</volume>
                <fpage>449</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">17270480</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kamphoven.2004.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamphoven</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Ruiter</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkel</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Hout</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bijman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Zeeuw</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoeve</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Zanten</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.</article-title>
                <source>Neurobiol Dis</source>
                <volume>16</volume>
                <fpage>14</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">15207257</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kishnani.2013.2431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amartino</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <collab>Pompe Registry Boards of Advisors</collab>
                </person-group>
                <article-title>Timing of diagnosis of patients with Pompe disease: data from the Pompe registry.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2013</year>
                <volume>161A</volume>
                <fpage>2431</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">23997011</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kishnani.2009.329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leslie</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruskin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van der Ploeg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clancy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jokic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Meara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.</article-title>
                <source>Pediatr Res.</source>
                <volume>66</volume>
                <fpage>329</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">19542901</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kishnani.2010.26">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldenberg</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeArmey</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benjamin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeberl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>99</volume>
                <fpage>26</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">19775921</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kishnani.2006a.671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yong</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006a</year>
                <article-title>A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.</article-title>
                <source>J Pediatr</source>
                <volume>148</volume>
                <fpage>671</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16737883</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kishnani.2006b.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crowley</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Downs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howell</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kravitz</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsden</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Grady</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patterson</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapoport</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slonim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tifft</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2006b</year>
                <article-title>Pompe disease diagnosis and management guideline.</article-title>
                <source>Genet Med</source>
                <volume>8</volume>
                <fpage>267</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">16702877</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.ko.1999.380">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ko</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>YW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tseng</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwa</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuang</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Molecular genetic study of Pompe disease in Chinese patients in Taiwan.</article-title>
                <source>Hum Mutat</source>
                <volume>13</volume>
                <fpage>380</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10338092</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.kravitz.2005.a186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kravitz</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeArmey</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pulmonary function findings in patients with infantile Pompe disease.</article-title>
                <source>Proc Am Thorac Soc</source>
                <volume>2</volume>
                <fpage>A186</fpage>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.labrousse.2010.379">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Labrousse</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pomponio</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akmaev</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholl</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>99</volume>
                <fpage>379</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">20080426</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.lafor_t.2000.1122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puech</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poenaru</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation.</article-title>
                <source>Neurology</source>
                <volume>55</volume>
                <fpage>1122</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11071489</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.lafor_t.2008.2063">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petiot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orlikowski</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellegrini</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Froissart</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petitjean</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabriat</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadrane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Annane</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease.</article-title>
                <source>Neurology.</source>
                <year>2008</year>
                <volume>70</volume>
                <fpage>2063</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18505979</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.lai.2016.1617">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuang</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niu</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy.</article-title>
                <source>J Child Neurol</source>
                <volume>31</volume>
                <fpage>1617</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">27655474</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.levine.2008.1033">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herlong</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>JS</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.</article-title>
                <source>Pediatr Cardiol.</source>
                <volume>29</volume>
                <fpage>1033</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">18661169</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.lin.1987.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsiao</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>YR</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>10</volume>
                <fpage>11</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3106710</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.lin.2017.842">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Violante</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orsini</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caggana</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevens</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiAntonio</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hong</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghomashchi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornreich</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasserstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Liquid chromatography-tandem mass spectrometry assay of leukocyte acid alpha-glucosidase for post newborn screening evaluation of Pompe disease.</article-title>
                <source>Clin Chem</source>
                <year>2017</year>
                <volume>63</volume>
                <fpage>842</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">28196920</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.mah.2010.502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mah</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cloutier</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeRuisseau</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conlon</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cresawn</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraites</surname>
                    <given-names>TJ</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Campbell-Thompson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuller</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.</article-title>
                <source>Mol Ther.</source>
                <volume>18</volume>
                <fpage>502</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">20104213</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.martiniuk.1998.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martiniuk</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mack</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arvanitopoulos</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rom</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Codd</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alcabes</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raben</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plotz</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease.</article-title>
                <source>Am J Med Genet</source>
                <volume>79</volume>
                <fpage>69</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">9738873</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.mccready.2007.325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McCready</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carson</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraborty</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skomorowski</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamforth</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rupar</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>92</volume>
                <fpage>325</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">17723315</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.mechtler.2012.335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mechtler</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stary</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metz</surname>
                    <given-names>TF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jesus</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greber-Platzer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herkner</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Streubel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.</article-title>
                <source>Lancet</source>
                <volume>379</volume>
                <fpage>335</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">22133539</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.meikle.1999.249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meikle</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopwood</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clague</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>WF</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Prevalence of lysosomal storage disorders.</article-title>
                <source>JAMA</source>
                <volume>281</volume>
                <fpage>249</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">9918480</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.messinger.2012.135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Messinger</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendelsohn</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dimmock</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hershkovitz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Champion</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.</article-title>
                <source>Genet Med</source>
                <volume>14</volume>
                <fpage>135</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">22237443</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.montalvo.2006.999">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Montalvo</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnarumma</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Filippi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dardis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroppiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pittis</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>999</fpage>
                <lpage>1006</lpage>
                <pub-id pub-id-type="pmid">16917947</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.nicolino.2009.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nicolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wraith</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leslie</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freyer</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pivnick</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ottinger</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loo</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smitka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jardine</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tat&#x000f2;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrol</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCandless</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skrinar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rangachari</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.</article-title>
                <source>Genet Med.</source>
                <volume>11</volume>
                <fpage>210</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19287243</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.oda.2011.560">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oda</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migita</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosuga</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukushi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okumiya</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okuyama</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Newborn screening for Pompe disease in Japan.</article-title>
                <source>Mol Genet Metab</source>
                <volume>104</volume>
                <fpage>560</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21963784</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.oktenli.2000.412">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oktenli</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Renal magnesium wasting, hypomagnesemic hypocalcemia, hypocalciuria and osteopenia in a patient with glycogenosis type II.</article-title>
                <source>Am J Nephrol</source>
                <volume>20</volume>
                <fpage>412</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11093001</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.pinto.2004.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pinto</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caseiro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocha</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacerda</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amaral</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sa Miranda</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Prevalence of lysosomal storage diseases in Portugal.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>12</volume>
                <fpage>87</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">14685153</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.pittis.2008.e27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pittis</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnarumma</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montalvo</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dominissini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroppiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease.</article-title>
                <source>Hum Mutat</source>
                <volume>29</volume>
                <fpage>E27</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">18429042</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.winchester.2008.275">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winchester</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodamer</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cupler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fumi&#x00107;</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacerda</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledvinov&#x000e1;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lugowska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukacs</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piraud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rupar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinigerska</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szlago</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verheijen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wuyts</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zakharova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2008</year>
                <article-title>Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>93</volume>
                <fpage>275</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">18078773</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.poorthuis.1999.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijer</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jong</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Weely</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niezen-Koning</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>The frequency of lysosomal storage diseases in The Netherlands.</article-title>
                <source>Hum Genet</source>
                <volume>105</volume>
                <fpage>151</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10480370</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.prater.2012.800">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prater</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banugaria</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dearmey</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botha</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stege</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phornphutkul</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>RY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>The emerging phenotype of long-term survivors with infantile Pompe disease.</article-title>
                <source>Genet Med</source>
                <volume>14</volume>
                <fpage>800</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">22538254</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.raben.2002.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raben</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plotz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).</article-title>
                <source>Curr Mol Med</source>
                <volume>2</volume>
                <fpage>145</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">11949932</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.roberts.2011.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Case</surname>
                    <given-names>LE</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry.</article-title>
                <source>Mol Genet Metab</source>
                <volume>104</volume>
                <fpage>574</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">21930409</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.sacconi.2010.1730">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sacconi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bocquet</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanalet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanant</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salviati</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnuelle</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Abnormalities of cerebral arteris are frequent in patients with late-onset Pompe disease.</article-title>
                <source>J Neurol.</source>
                <volume>257</volume>
                <fpage>1730</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">20559845</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.sacconi.2014.648">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sacconi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahbi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theodore</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salviati</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouhour</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vial</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duboc</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laforet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnuelle</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>24</volume>
                <fpage>648</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">24844452</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.shieh.1998.306">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shieh</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>CY</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect.</article-title>
                <source>Hum Mutat</source>
                <volume>11</volume>
                <fpage>306</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">9554747</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.slonim.2000.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Slonim</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bulone</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martiniuk</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Identification of two subtypes of infantile acid maltase deficiency.</article-title>
                <source>J Pediatr</source>
                <volume>137</volume>
                <fpage>283</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10931430</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.smith.2017.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernot</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcus</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Islam</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shafi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>2017</year>
                <article-title>Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity.</article-title>
                <source>Exp Neurol.</source>
                <volume>287</volume>
                <fpage>216</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">27453480</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.strothotte.2010.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strothotte</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strigl-Pill</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunert</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornblum</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eger</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wessig</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breunig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glocker</surname>
                    <given-names>FX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vielhaber</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brejova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reiners</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spranger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.</article-title>
                <source>J Neurol.</source>
                <volume>257</volume>
                <fpage>91</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19649685</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.tabarki.2002.697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tabarki</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahdhaoui</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yacoub</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selmi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahdhaoui</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouraoui</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ernez</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jridi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ammar</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Essoussi</surname>
                    <given-names>AS</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Familial hypertrophic cardiomyopathy associated with Wolff-Parkinson-White syndrome revealing type II glycogenosis.</article-title>
                <source>Arch Pediatr</source>
                <volume>9</volume>
                <fpage>697</fpage>
                <lpage>700</lpage>
                <pub-id pub-id-type="pmid">12162158</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.van_capelle.2010.597">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Capelle</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goedegebure</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Homans</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoeve</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hearing loss in Pompe disease revisited: results from a study of 24 children.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <fpage>597</fpage>
                <lpage>602</lpage>
                <pub-id pub-id-type="pmid">20596893</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.van_der_beek.2011.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Beek</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Capelle</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Velden-van Etten</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stam</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2011</year>
                <month>Sep-Oct</month>
                <volume>104</volume>
                <fpage>129</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">21763167</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.van_den_hout.2003.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van den Hout</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakker</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loonen</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Klerk</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.</article-title>
                <source>Pediatrics</source>
                <volume>112</volume>
                <fpage>332</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">12897283</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.van_der_kraan.1994.1535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van der Kraan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroos</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joosse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bijvoet</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbeet</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijer</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Deletion of exon 18 is a frequent mutation in glycogen storage disease type II.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>203</volume>
                <fpage>1535</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">7945303</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.van_der_ploeg.2010.1396">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clemens</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Escolar</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florence</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groeneveld</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lake</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lange</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leshner</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayhew</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nozaki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pestronk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbloom</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skrinar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Capelle</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Beek</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasserstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zivkovic</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A randomized study of alglucosidase alfa in late-onset Pompe's disease.</article-title>
                <source>N Engl J Med.</source>
                <volume>362</volume>
                <fpage>1396</fpage>
                <lpage>406</lpage>
                <pub-id pub-id-type="pmid">20393176</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.van_gelder.2012.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Gelder</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Capelle</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebbink</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moor-van Nugteren</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Hout</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakkesteegt</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Gier</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy.</article-title>
                <source>J. Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>505</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">22008944</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.winchester.2008.275_1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winchester</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodamer</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cupler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fumi&#x00107;</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacerda</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledvinov&#x000e1;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lugowska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukacs</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piraud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rupar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinigerska</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szlago</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verheijen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wuyts</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zakharova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2008</year>
                <article-title>Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>93</volume>
                <fpage>275</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">18078773</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.winkel.2005.875">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winkel</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagemans</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Doorn</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loonen</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuser</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The natural course of non-classic Pompe's disease; a review of 225 published cases.</article-title>
                <source>J Neurol</source>
                <volume>252</volume>
                <fpage>875</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">16133732</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.yang.2016">
              <mixed-citation publication-type="other">Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, Lai CJ, Chu TH, Yang TF, Hsu TR, Soong WJ, Niu DM (2016) Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr 169, 174-80 e1.</mixed-citation>
            </ref>
            <ref id="gsd2.REF.young.2012.50">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piraud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laforet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bashir</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.</article-title>
                <source>Am J Med Genet C Semin Med Genet.</source>
                <year>2012</year>
                <volume>160C</volume>
                <fpage>50</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22252961</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.young.2009.536">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thurberg</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.</article-title>
                <source>Genet Med.</source>
                <year>2009</year>
                <volume>11</volume>
                <fpage>536</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">19521244</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.zampieri.2011.422">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zampieri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buratti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dominissini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montalvo</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pittis</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dardis</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Slicing mutations in glycogen-storage disease Type II: evaluation of the full spectrum of mutations and their relation to patients&#x02019; phenotypes.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>19</volume>
                <fpage>422</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">21179066</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.zhang.2006.302">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kallwass</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carr</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keutzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease.</article-title>
                <source>Genet Med</source>
                <volume>8</volume>
                <fpage>302</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16702880</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gsd2.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="gsd2.Suggested_Reading.reflist0">
            <ref id="gsd2.REF.american_association_of_neuromuscular__electrodiagnostic_medicine.2009.149">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>American Association of Neuromuscular &#x00026; Electrodiagnostic Medicine</collab>
                </person-group>
                <year>2009</year>
                <article-title>Diagnostic criteria for late-onset (childhood and adult) Pompe disease.</article-title>
                <source>Muscle Nerve.</source>
                <volume>40</volume>
                <fpage>149</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">19533647</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd2.REF.hirschhorn">
              <mixed-citation publication-type="book">Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: (acid maltase) deficiency. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> New York, NY: McGraw-Hill. Chap 135. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="gsd2.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="gsd2.Author_Notes">
          <title>Author Notes</title>
          <p><bold>Web:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cincinnatichildrens.org/service/s/star/default/">STAR Center for Lysosomal Diseases</ext-link></p>
        </sec>
        <sec id="gsd2.Author_History">
          <title>Author History</title>
          <p>Laurie Bailey, MS (2017-present)Nancy Leslie, MD (2007-present)Brad Tinkle, MD, PhD; Advocate Children&#x02019;s Hospital, Illinois (2007-2017)</p>
        </sec>
        <sec id="gsd2.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 May 2017 (bp) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 May 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>12 August 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 August 2008 (cd) Revision: deletion/duplication testing available clinically</p>
            </list-item>
            <list-item>
              <p>22 April 2008 (cd) Revision: targeted mutation analysis no longer available clinically</p>
            </list-item>
            <list-item>
              <p>31 August 2007 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>8 January 2007 (bt) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
